Novartis reported $9.96B in Trade Debtors for its fiscal quarter ending in September of 2026.





Trade Debtors Change Date
AbbVie USD 13.82B 1.34B Jun/2026
Amgen USD 10.35B 126M Sep/2026
AstraZeneca USD 18.87B 11M Sep/2026
Bausch Health Companies USD 2.53B 270M Sep/2026
Biogen USD 2.38B 15.8M Sep/2026
Bristol-Myers Squibb USD 12.85B 976M Sep/2026
Canopy Growth CAD 42.59M 6.3M Jun/2026
Corcept Therapeutics USD 111.06M 34.14M Sep/2026
Drreddys Laboratories INR 101.4B 21.77B Sep/2026
Eli Lilly USD 23.48B 2.3B Jun/2026
Gilead Sciences USD 5.06B 314M Jun/2026
GlaxoSmithKline GBP 8.52B 451M Sep/2026
Glaxosmithkline GBP 11.31B 814.23M Sep/2026
J&J USD 19.05B 3.49B Jun/2026
Merck USD 12.56B 354M Jun/2026
Novartis USD 9.96B 109M Sep/2026
Novartis USD 9.96B 361M Sep/2026
Perrigo USD 685.5M 24.4M Sep/2026
Pfizer USD 17.57B 1.38B Sep/2026
Phibro Animal Health USD 215.87M 2.02M Dec/2025
Prestige Brands USD 187.36M 4.56M Jun/2026
Roche Holding CHF 13.34B 1.44B Jun/2026
Sanofi EUR 326M 166M Sep/2026
Sanofi EUR 492M 10M Jun/2026
Supernus Pharmaceuticals USD 211.66M 29.47M Jun/2026
Zoetis USD 1.69B 121M Sep/2026